Another therapeutic approach could be to reactivate apoptotic pathways via inhibiting anti-apoptotic proteins Bcl-2 and Bcl-xL, which supposedly play an important role in chondrosarcoma chemoresistance, because inhibition of anti-apoptotic proteins increased sensitivity towards cisplatin and doxorubicin [64]. The gene discussed is BCL2L1; the disease is chondrosarcoma.